Haemonetics Statistics
Total Valuation
Haemonetics has a market cap or net worth of $4.52 billion. The enterprise value is $5.15 billion.
| Market Cap | 4.52B |
| Enterprise Value | 5.15B |
Important Dates
The next confirmed earnings date is Thursday, August 8, 2024, before market open.
| Earnings Date | Aug 8, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Haemonetics has 50.95 million shares outstanding. The number of shares has decreased by -0.04% in one year.
| Shares Outstanding | 50.95M |
| Shares Change (YoY) | -0.04% |
| Shares Change (QoQ) | -0.08% |
| Owned by Insiders (%) | 0.94% |
| Owned by Institutions (%) | 102.71% |
| Float | 50.31M |
Valuation Ratios
The trailing PE ratio is 38.75 and the forward PE ratio is 19.12. Haemonetics's PEG ratio is 1.63.
| PE Ratio | 38.75 |
| Forward PE | 19.12 |
| PS Ratio | 3.45 |
| Forward PS | 3.20 |
| PB Ratio | 4.71 |
| P/FCF Ratio | 38.55 |
| PEG Ratio | 1.63 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 19.65, with an EV/FCF ratio of 43.92.
| EV / Earnings | 43.81 |
| EV / Sales | 3.93 |
| EV / EBITDA | 19.65 |
| EV / EBIT | 31.23 |
| EV / FCF | 43.92 |
Financial Position
The company has a current ratio of 2.56, with a Debt / Equity ratio of 0.84.
| Current Ratio | 2.56 |
| Quick Ratio | 1.28 |
| Debt / Equity | 0.84 |
| Debt / EBITDA | 3.08 |
| Debt / FCF | 6.89 |
| Interest Coverage | 12.67 |
Financial Efficiency
Return on equity (ROE) is 12.80% and return on invested capital (ROIC) is 7.22%.
| Return on Equity (ROE) | 12.80% |
| Return on Assets (ROA) | 5.60% |
| Return on Capital (ROIC) | 7.22% |
| Revenue Per Employee | $357,959 |
| Profits Per Employee | $32,146 |
| Employee Count | 3,657 |
| Asset Turnover | 0.63 |
| Inventory Turnover | 2.14 |
Taxes
In the past 12 months, Haemonetics has paid $34.31 million in taxes.
| Income Tax | 34.31M |
| Effective Tax Rate | 22.59% |
Stock Price Statistics
The stock price has decreased by -3.54% in the last 52 weeks. The beta is 0.29, so Haemonetics's price volatility has been lower than the market average.
| Beta (5Y) | 0.29 |
| 52-Week Price Change | -3.54% |
| 50-Day Moving Average | 88.05 |
| 200-Day Moving Average | 84.54 |
| Relative Strength Index (RSI) | 54.51 |
| Average Volume (20 Days) | 586,230 |
Short Selling Information
The latest short interest is 4.22 million, so 8.29% of the outstanding shares have been sold short.
| Short Interest | 4.22M |
| Short Previous Month | 3.26M |
| Short % of Shares Out | 8.29% |
| Short % of Float | 8.40% |
| Short Ratio (days to cover) | 5.98 |
Income Statement
In the last 12 months, Haemonetics had revenue of $1.31 billion and earned $117.56 million in profits. Earnings per share was $2.29.
| Revenue | 1.31B |
| Gross Profit | 691.55M |
| Operating Income | 164.88M |
| Pretax Income | 151.87M |
| Net Income | 117.56M |
| EBITDA | 262.10M |
| EBIT | 164.88M |
| Earnings Per Share (EPS) | $2.29 |
Balance Sheet
The company has $178.80 million in cash and $807.79 million in debt, giving a net cash position of -$628.99 million or -$12.34 per share.
| Cash & Cash Equivalents | 178.80M |
| Total Debt | 807.79M |
| Net Cash | -628.99M |
| Net Cash Per Share | -$12.34 |
| Equity (Book Value) | 959.96M |
| Book Value Per Share | 18.84 |
| Working Capital | 468.52M |
Cash Flow
In the last 12 months, operating cash flow was $181.75 million and capital expenditures -$64.49 million, giving a free cash flow of $117.27 million.
| Operating Cash Flow | 181.75M |
| Capital Expenditures | -64.49M |
| Free Cash Flow | 117.27M |
| FCF Per Share | $2.31 |
Margins
Gross margin is 52.83%, with operating and profit margins of 12.60% and 8.98%.
| Gross Margin | 52.83% |
| Operating Margin | 12.60% |
| Pretax Margin | 11.60% |
| Profit Margin | 8.98% |
| EBITDA Margin | 20.02% |
| EBIT Margin | 12.60% |
| FCF Margin | 8.96% |
Dividends & Yields
Haemonetics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.04% |
| Shareholder Yield | 0.04% |
| Earnings Yield | 2.60% |
| FCF Yield | 2.59% |
Analyst Forecast
The average price target for Haemonetics is $109.50, which is 23.41% higher than the current price. The consensus rating is "Buy".
| Price Target | $109.50 |
| Price Target Difference | 23.41% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 10.72% |
| EPS Growth Forecast (5Y) | 39.39% |
Stock Splits
The last stock split was on December 3, 2012. It was a forward split with a ratio of 2:1.
| Last Split Date | Dec 3, 2012 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
Haemonetics has an Altman Z-Score of 3.53 and a Piotroski F-Score of 7.
| Altman Z-Score | 3.53 |
| Piotroski F-Score | 7 |